Cipla not infringing Pfizer patent for drug Tarceva: DHC

In a big relief to pharmaceutical company Cipla Ltd. (“Cipla”), the Delhi High Court ruled that Cipla did not infringe OSI/Pfizer (“Pfizer”) Indian patent for their drug ‘Erlotinib’ (trade name ‘Tarceva’) by manufacture, marketing and sale of their drug ‘Erlocip’, and hence denied permanent injunction in favour of Pfizer.

‘Traceva’ is used to destroy some types of cancer cells while causing little harm to the normal human cells.

However, the court also ruled out revoking Pfizer’s patent on the grounds of non-disclosure (concealments) of information to Patent Office and being violative of Section 3(d) of the Patent Act.

About DSLegal

A full service international law firm based in New Delhi with an office in Chicago, USA.
This entry was posted in Intellectual Property Law and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s